CS
ANTX icon

Credit Suisse’s AN2 Therapeutics ANTX Stock Holding History

Credit Suisse’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$86.5K Buy
+26,630
New +$290K ﹤0.01% 2936
2022
Q4 		– Sell
-26
Closed – – 3952
2022
Q3 		$0 Buy
26
+24
+1,200% +$280 ﹤0.01% 4026
2022
Q2 		$0 Buy
+2
New +$26 ﹤0.01% 3903

Other funds holding ANTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Credit Suisse's ANTX Position: Q1 2024 in Review

Credit Suisse opened a new position in AN2 Therapeutics (ANTX) in Q1 2024: 26,630 shares worth $86.5K. The stake represents ﹤0.01% of the portfolio and ranks #2936 among its holdings. This is a return to the name: Credit Suisse previously reported a position in ANTX as recently as Q3 2022.

Credit Suisse first reported a position in ANTX in Q2 2022 and has held it in 3 quarters since. 54 funds tracked by Wall St. Rank hold ANTX as of Q1 2024.

  • Credit Suisse held 26,630 shares of AN2 Therapeutics worth $86.5K as of Q1 2024.
  • AN2 Therapeutics was a new Credit Suisse position in Q1 2024.
  • AN2 Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2936 holding.
  • Credit Suisse first reported a position in AN2 Therapeutics in Q2 2022 and has held it in 3 quarters since.
  • 54 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.